Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment
出版年份 2019 全文链接
标题
Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori
treatment
作者
关键词
-
出版物
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume 49, Issue 11, Pages 1385-1394
出版商
Wiley
发表日期
2019-04-25
DOI
10.1111/apt.15273
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Primary antibiotic resistance of Helicobacter pylori in Chinese patients: a multiregion prospective 7-year study
- (2018) D.-S. Liu et al. CLINICAL MICROBIOLOGY AND INFECTION
- Prevalence of antibiotic resistance in Helicobacter pylori : a systematic review and meta-analysis in World Health Organization regions
- (2018) Alessia Savoldi et al. GASTROENTEROLOGY
- Comparative study of Helicobacter pylori eradication rates of concomitant therapy vs modified quadruple therapy comprising proton-pump inhibitor, bismuth, amoxicillin, and metronidazole in Korea
- (2018) Jung Wan Choe et al. HELICOBACTER
- Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection
- (2018) Wen Zhong Liu et al. HELICOBACTER
- Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial
- (2018) Hassan Salmanroghani et al. PLoS One
- Relative potency of proton-pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI
- (2018) David Y. Graham et al. HELICOBACTER
- Illusions regardingHelicobacter pyloriclinical trials and treatment guidelines
- (2017) David Y Graham GUT
- Helicobacter pylori infection and antibiotic resistance: a WHO high priority?
- (2017) Bich N. Dang et al. Nature Reviews Gastroenterology & Hepatology
- Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy
- (2016) Qi Chen et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Helicobacter pyloritherapy: a paradigm shift
- (2016) David Y. Graham et al. Expert Review of Anti-Infective Therapy
- Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report
- (2016) P Malfertheiner et al. GUT
- Role of bismuth in improvingHelicobacter pylorieradication with triple therapy
- (2016) Maria Pina Dore et al. GUT
- Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
- (2016) Jyh-Ming Liou et al. LANCET
- Inefficacy of triple therapy and comparison of two different bismuth-containing quadruple regimens as a firstline treatment option for helicobacter pylori
- (2016) Murat Kekilli et al. Saudi Journal of Gastroenterology
- Empiric H. pylori therapy—10-day concomitant, bismuth quadruple or 14-day triple therapy: none is best
- (2016) Yoshio Yamaoka et al. Translational Cancer Research
- Seven-Day Bismuth-based Quadruple Therapy as an Initial Treatment for Helicobacter pylori Infection in a High Metronidazole Resistant Area
- (2015) Ratha-korn Vilaichone et al. Asian Pacific Journal of Cancer Prevention
- How to Effectively Use Bismuth Quadruple Therapy
- (2015) David Y. Graham et al. GASTROENTEROLOGY CLINICS OF NORTH AMERICA
- Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-lineHelicobacter pyloritherapy
- (2015) Wei Zhang et al. GUT
- Antimicrobial Susceptibility-Guided Therapy Versus Empirical Concomitant Therapy for Eradication ofHelicobacter pyloriin a Region with High Rate of Clarithromycin Resistance
- (2015) Angel Cosme et al. HELICOBACTER
- Tailored versus Triple plus Bismuth or Concomitant Therapy as InitialHelicobacter pyloriTreatment: A Randomized Trial
- (2015) Liya Zhou et al. HELICOBACTER
- Azithromycin versus Doxycycline for Urogenital Chlamydia trachomatis Infection
- (2015) William M. Geisler et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pretreatment Antimicrobial Susceptibility-Guided Vs. Clarithromycin-Based Triple Therapy for Helicobacter pylori Eradication in a Region With High Rates of Multiple Drug Resistance
- (2014) Chung-Su Park et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Prospective multi-region study on primary antibiotic resistance of Helicobacter pylori strains isolated from Chinese patients
- (2014) Zhiqiang Song et al. DIGESTIVE AND LIVER DISEASE
- Efficacy of TailoredHelicobacter pyloriEradication Treatment Based on Clarithromycin Susceptibility and Maintenance of Acid Secretion
- (2014) Mitsushige Sugimoto et al. HELICOBACTER
- Evidence-based recommendations for successfulHelicobacter pyloritreatment
- (2014) Jeng-Yih Wu et al. Expert Review of Gastroenterology & Hepatology
- Rational Helicobacter pylori Therapy: Evidence-Based Medicine Rather Than Medicine-Based Evidence
- (2013) David Y. Graham et al. Clinical Gastroenterology and Hepatology
- Effect of dosing schemes of amoxicillin on eradication rates ofHelicobacter pyloriwith amoxicillin-based triple therapy
- (2013) Takahisa Furuta et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Helicobacter pyloriresistance to antibiotics in Europe and its relationship to antibiotic consumption
- (2012) Francis Megraud et al. GUT
- Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial
- (2011) Peter Malfertheiner et al. LANCET
- Pharmacologic Aspects of Eradication Therapy for Helicobacter pylori Infection
- (2010) Takahisa Furuta et al. GASTROENTEROLOGY CLINICS OF NORTH AMERICA
- Tailored eradication therapy based on fecalHelicobacter pyloriclarithromycin sensitivities
- (2008) Takashi Kawai et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started